Alomari Munther, Balasamy Rabindran Jermy, Almohazey Dana, Ravinayagam Vijaya, Al Hamad Mohammad, Ababneh Deena, Bahmdan Hiba, Alomari Abdul-Hakeem, Mokadem Zakaria, Elaissari Abdelhamid
Department of Stem Cell Biology, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Department of Nano-Medicine Research, Institute for Research and Medical Consultations, Imam Abdulrahman Bin Faisal University, Dammam 31441, Saudi Arabia.
Polymers (Basel). 2020 Jul 8;12(7):1516. doi: 10.3390/polym12071516.
Tamoxifen (TAM) is a hormonal drug and is mainly used as an anti-estrogen in breast cancer patients. TAM binds to estrogen receptors (ERs), resulting in inhibition of estrogen signaling pathways and thus, a downregulation of cell proliferation. Cancer cells with negative or low ER expression will not uptake TAM and will show low response. Poly (methyl methacrylate) (PMMA) nanoparticles were prepared using surfactant-free emulsion polymerization, then were loaded with Nile red (NR), which resulted in PMMA-NR. To enhance TAM delivery to cervical cancer cells (HELA), which is considered ER-negative, we loaded TAM and polymethyl methacrylate nanoparticles-Nile-red into silica (PMMA-NR-Si-TAM). The uptake and intracellular distribution were visualized by confocal laser scanning microscopy, and the in vitro cytotoxic activity was evaluated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay using HELA and non-tumorigenic cell line HFF-1. The sensitivity of HELA (LC50: 207.31 µg/mL) and HFF-1 (LC50: 234.08 µg/mL) to free TAM was very low. However, after the encapsulation of TAM with PMMA-NR, the sensitivity significantly increased HELA (LC50: 71.83 µg/mL) and HFF-1 (LC50: 37.36 µg/mL). This indicates that TAM can be used for the treatment of ER-negative cervical cancer once conjugated to PMMA-NR nanoparticles. In addition, the PMMA-NR formulation appears to be highly suitable for cancer imaging and drug delivery.
他莫昔芬(TAM)是一种激素药物,主要用作乳腺癌患者的抗雌激素药物。TAM与雌激素受体(ERs)结合,导致雌激素信号通路受到抑制,从而使细胞增殖下调。ER表达阴性或低表达的癌细胞不会摄取TAM,反应也较低。采用无表面活性剂乳液聚合法制备聚甲基丙烯酸甲酯(PMMA)纳米颗粒,然后负载尼罗红(NR),得到PMMA-NR。为了增强TAM向被认为ER阴性的宫颈癌细胞(HELA)的递送,我们将TAM和聚甲基丙烯酸甲酯纳米颗粒-尼罗红负载到二氧化硅中(PMMA-NR-Si-TAM)。通过共聚焦激光扫描显微镜观察摄取和细胞内分布,并使用HELA和非致瘤细胞系HFF-1通过MTT(3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐)法评估体外细胞毒性活性。HELA(半数致死浓度:207.31 µg/mL)和HFF-1(半数致死浓度:234.08 µg/mL)对游离TAM的敏感性非常低。然而,用PMMA-NR包裹TAM后,HELA(半数致死浓度:71.83 µg/mL)和HFF-1(半数致死浓度:37.36 µg/mL)的敏感性显著增加。这表明TAM一旦与PMMA-NR纳米颗粒缀合,可用于治疗ER阴性宫颈癌。此外,PMMA-NR制剂似乎非常适合癌症成像和药物递送。